Herantis Pharma
1,475 EUR -2,32%4.126 investorer følger denne virksomhed
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
Læs mereP/E (adj.) (24e)
-5,66
EV/EBIT (adj.) (24e)
-5,67
P/B (24e)
141,61
Udbytteafkast, % (24e)
-
Kursmål
2.20 EUR
Anbefaling
Akkumulér
Opdateret
23.8.2024
First North Finland
HRTIS
Daglig lav / høj pris
1,475 / 1,565
EUR
Markedsværdi
29,74 mio. EUR
Aktieomsætning
11,24 t EUR
Volumen
7,5 t
Business risk
Valuation risk
Current
Previous
Seneste analyser
Extensive report
Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the reportAnalytiker
Antti Siltanen
Analytiker
Resultatopgørelse
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| Omsætning | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
| vækst-% | 150,0 % | |||||||
| EBITDA | -8,5 | -9,7 | -8,1 | 0,2 | -5,3 | -5,0 | -5,4 | -6,0 |
| EBIT (adj.) | -8,1 | -12,5 | -8,0 | 0,2 | -5,3 | -5,0 | -5,4 | -6,0 |
| EBIT | -8,1 | -12,5 | -8,0 | 0,2 | -5,3 | -5,0 | -5,4 | -6,0 |
| Overskud før skat | -8,6 | -12,8 | -9,3 | 0,3 | -5,3 | -5,0 | -5,4 | -6,0 |
| Netto indkomst | -8,6 | -12,8 | -9,3 | 0,3 | -5,3 | -5,0 | -5,4 | -6,0 |
| EPS (adj.) | -0,88 | -1,15 | -0,55 | 0,01 | -0,26 | -0,21 | -0,23 | -0,25 |
| vækst-% | -1.983,9 % | |||||||
| Udbytte | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| Udbytte ratio |
Lønsomhed og afkast på kapital
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| EBITDA-% | -213.375,0 % | -243.525,0 % | -201.825,0 % | 3.850,0 % | -52.560,0 % | -49.520,0 % | -54.342,5 % | -59.532,9 % |
| EBIT-% (adj.) | -201.775,0 % | -311.525,0 % | -199.825,0 % | 3.850,0 % | -52.560,0 % | -49.520,0 % | -54.342,5 % | -59.532,9 % |
| EBIT-% | -201.775,0 % | -311.525,0 % | -199.825,0 % | 3.850,0 % | -52.560,0 % | -49.520,0 % | -54.342,5 % | -59.532,9 % |
| ROE | -226,6 % | -396,1 % | 1.541,2 % | 12,0 % | -213,4 % | -2.116,2 % | 221,0 % | 73,0 % |
| ROI | -109,1 % | -119,5 % | -151,8 % | 3,3 % | -139,4 % | -180,1 % | -362,3 % | -2.381,3 % |
Værdiansættelse
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| Aktiekurs (EUR) | 4,15 | 2,40 | 1,65 | 1,58 | 1,48 | 1,48 | 1,48 | 1,48 |
| Aktier | 9,8 | 11,1 | 16,9 | 20,2 | 20,2 | 23,9 | 23,9 | 23,9 |
| Markedsværdi | 40,5 | 26,6 | 27,9 | 31,9 | 29,7 | 35,2 | 35,2 | 35,2 |
| Enterprise value | 34,4 | 26,4 | 26,5 | 25,4 | 29,8 | 35,2 | 40,6 | 46,6 |
| EV/S | 8.593,4 | 6.606,4 | 6.613,7 | 6.360,3 | 2.977,7 | 3.518,7 | 4.062,1 | 4.657,4 |
| EV/EBITDA | - | - | - | 165,2 | - | - | - | - |
| EV/EBIT (adj.) | - | - | - | 165,2 | - | - | - | - |
| EV/EBIT | - | - | - | 165,2 | - | - | - | - |
| P/E (adj.) | - | - | - | 114,2 | - | - | - | - |
| P/E | - | - | - | 114,2 | - | - | - | - |
| P/B | 5,3 | - | - | 6,8 | 141,6 | 136,4 | - | - |
| P/S | 10.122,9 | 6.662,4 | 6.976,2 | 7.963,6 | 2.973,7 | 3.519,5 | 3.519,5 | 3.519,5 |
| Udbytteprocent | ||||||||
| Equity ratio | 46,2 % | -14,7 % | -1,1 % | 69,9 % | 7,6 % | 9,4 % | -2.070,5 % | -4.451,8 % |
| Gearing ratio | -80,6 % | 19,6 % | 2.071,4 % | -136,0 % | 19,0 % | -3,1 % | -104,8 % | -102,2 % |
Kvartalsdata
| Q1/23 | Q2/23 | Q3/23 | Q4/23 | 2023 | Q1/24e | Q2/24e | Q3/24e | Q4/24e | |
|---|---|---|---|---|---|---|---|---|---|
| Omsætning | 0,0 | 0,0 | 0,0 | ||||||
| EBITDA | -2,4 | 2,6 | 0,2 | -2,8 | -2,5 | ||||
| EBIT | -2,4 | 2,6 | 0,2 | -2,8 | -2,5 | ||||
| Overskud før skat | -1,8 | 2,1 | 0,3 | -2,8 | -2,5 | ||||
| Netto indkomst | -1,8 | 2,1 | 0,3 | -2,8 | -2,5 |
ViserAlle indholdstyper
Herantis receives approval for Phase Ib clinical trial
Herantis Pharma announces approval of clinical trial application for a Phase 1b trial with HER-096 in Parkinson’s disease
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Herantis Pharma participating at Sachs, Nordic Life Science days and Finnish investor conferences in August and September
Herantis H1'24: The next trial phase will begin in H2 as expected
Herantis H1'24 flash comment: Phase Ib starts at the end of the year
Herantis Pharma, Webcast, Q2'24
Herantis H2'24 earnings preview: Towards Phase Ib studies
Herantis Pharma publishes 1H 2024 report today
Herantis Pharma: Invitation to 1H 2024 report webinar on August 22, 2024
Herantis Pharma Oyj: Managers' Transactions – Henri Huttunen
Herantis Pharma Oyj: Managers' Transactions – Antti Vuolanto
Herantis Pharma Oyj: Managers' Transactions – Tone Kvåle
Herantis Pharma Plc's board decides on new option rights program for managing director, management team and other key personnel
Inside information: Herantis Pharma receives research funding from The Michael J. Fox Foundation, US and the Parkinson's Virtual Biotech, UK
Herantis Pharma: Disease-modifying drug for Parkinson’s
